Stockscreener 앱 받기
1.40
5.26%
0.07
시간 외 거래:
1.44
0.04
+2.86%
전일 마감가:
$1.33
열려 있는:
$1.32
하루 거래량:
742.24K
Relative Volume:
0.63
시가총액:
$292.50M
수익:
$889.00K
순이익/손실:
$-156.28M
주가수익비율:
-2.6581
EPS:
-0.5267
순현금흐름:
$-150.06M
1주 성능:
-17.16%
1개월 성능:
-13.58%
6개월 성능:
-30.69%
1년 성능:
-40.68%
1일 변동 폭
$1.31
$1.42
1주일 범위
$1.30
$1.68
52주 변동 폭
$1.30
$3.4799
Prokidney Corp Stock (PROK) Company Profile
명칭
Prokidney Corp
전화
336-999-7028
주소
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
1.40 | 277.87M | 889.00K | -156.28M | -150.06M | -0.5267 |
VRTX
Vertex Pharmaceuticals Inc
|
515.55 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.93 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
987.84 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.51 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-16 | 개시 | H.C. Wainwright | Buy |
| 2025-06-30 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-09-30 | 개시 | JP Morgan | Neutral |
| 2024-09-10 | 개시 | Guggenheim | Buy |
| 2024-03-07 | 재개 | Morgan Stanley | Equal-Weight |
| 2024-01-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-07-25 | 개시 | BTIG Research | Buy |
| 2022-12-21 | 개시 | Jefferies | Buy |
| 2022-11-10 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-10-18 | 개시 | UBS | Buy |
| 2022-10-14 | 개시 | Citigroup | Buy |
| 2022-09-23 | 개시 | BofA Securities | Buy |
| 2022-09-02 | 개시 | Evercore ISI | Outperform |
모두보기
Prokidney Corp 주식(PROK)의 최신 뉴스
ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade) (PROK) - Seeking Alpha
What is HC Wainwright's Estimate for ProKidney Q3 Earnings? - marketbeat.com
ProKidney Corp. (PROK) Slides 9.3% to $1.46 as Key Support Level Comes into FocusVolume Breakout Ideas - dars.gov.et
Morgan Stanley (PROK) filings show ProKidney stake at 4.7% and below 5% level - Stock Titan
ProKidney FY2030 EPS Estimate Decreased by HC Wainwright - marketbeat.com
ProKidney reports larger second-quarter loss as key clinical trial expenses mount - Winston-Salem Journal
ProKidney earnings missed, revenue topped estimates By Investing.com - Investing.com Nigeria
ProKidney Corp (PROK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ProKidney earnings missed, revenue topped estimates - Investing.com
ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
ProKidney completes Phase 3 PROACT 1 accelerated approval enrollment - scanx.trade
ProKidney (NASDAQ:PROK) Releases Earnings Results, Misses Estimates By $0.01 EPS - marketbeat.com
ProKidney reports Q2 revenue of $150,000 as PROACT 1 advances - Quiver Quantitative
Cell therapy developer ProKidney's Q2 operating loss widens as trial costs rise - TradingView
PROK: Completed key Phase 3 trial enrollment; cash supports operations into mid-2027 - TradingView
ProKidney Corp. (NASDAQ: PROK) warns on cash runway after $89M H1 loss - Stock Titan
ProKidney Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights - GlobeNewswire
ProKidney Corp (PROK) Stock News Today - TradingKey
ProKidney Corp. (PROK) director converts paired units into Class A stock - Stock Titan
3 Promising Penny Stocks With Market Caps Under $500M - simplywall.st
PROK Q2'26 Earnings: EPS estimate is (0.14) USD - TradingView
ProKidney (PROK) to Release Quarterly Earnings on Tuesday - marketbeat.com
ProKidney Corp. Revenue Breakdown – NASDAQ:PROK - TradingView
PROK Q2'26 Earnings: revenue estimate is 186.25K USD - TradingView
ProKidney Corp (PROK) Income Statement - TradingKey
PROK|ProKidney Corp|Price:1.565|Chg%:+0.025 - TradingKey
ProKidney Corp (PROK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ProKidney Corp (PROK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ProKidney Corp (PROK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ProKidney Corp (PROK) Balance Sheet - TradingKey
ProKidney Corp (PROK) Cash Flow - TradingKey
PROK|ProKidney Corp|Price:1.504|Chg%:+0.004 - TradingKey
ProKidney Corp. (PROK) Q1 2026 Earnings: Narrower Loss as Clinical Pipeline AdvancesFiscal Year Earnings - dars.gov.et
ProKidney Corp (PROK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ProKidney (NASDAQ:PROK) Trading Down 0.7%Time to Sell? - marketbeat.com
ProKidney Corp. (PROK) Q1 2026 Earnings: In-Line EPS, Pre-Revenue Progress Drives Modest Stock GainROA Comparison - dars.gov.et
Meet the Biotech Stock That Rocketed 775% Higher - MSN
ProKidney Corp (PROK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ProKidney Corp. Q1 2026 Earnings: Clinical-Stage Biotech Posts Narrower-Than-Expected Loss, Shares RallyEPS Revision Trend - dars.gov.et
ProKidney Corp. (PROK) Declines Sharply: Key Support Level Under ScrutinyMFI Overbought - dars.gov.et
ProKidney Corp. (PROK) Q1 2026 Earnings: Narrowed Loss Slightly Beats Estimates Amid Pipeline Focus - dars.gov.et
ProKidney (NASDAQ:PROK): Can This Penny Stock Rebound? - Kalkine Media
What Makes ProKidney Corp (NASDAQ:PROK) Stand Out on Nasdaq Composite? - Kalkine Media
ProKidney Corp. (PROK) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEstimate Uncertainty - dars.gov.et
ProKidney (PROK) 43rd Annual J.P. Morgan Healthcare Conference 2025 Summary - Quartr
ProKidney (NASDAQ: PROK) CTO awarded 750,000 stock options at $1.89 strike - Stock Titan
July 2026 Penny Stocks With Promising Potential - simplywall.st
PROK Q1 2026 Earnings: EPS Slightly Exceeds Estimates as Clinical Progress ContinuesRevenue Guidance Range - dars.gov.et
PROKProKidney Corp Short Interest - Finviz
Is ProKidney (NASDAQ:PROK) In A Good Position To Invest In Growth? - 富途牛牛
Prokidney Corp (PROK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Prokidney Corp 주식 (PROK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Pereira Brian JG | Director |
Nov 12 '25 |
Sale |
2.72 |
255,026 |
694,515 |
54,333 |
1.80%
1.77%
자본화:
|
볼륨(24시간):